Inferra AIResearch Tools

Inferra AI / Company / DHR

Danaher Corporation

DHR · Health Care

Last earnings Oct 21, 2026

Key results

Net incomequarter

$908 million

Key Third Quarter 2025 Results Net earnings were $908 million, or $1.27 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.89.

SEC original ↗Danaher Corporation — Earnings release (8-K exhibit)EX-99Oct 21, 2025

Revenuequarter

4.5%

Revenues increased 4.5% year-over-year to $6.1 billion and non-GAAP core revenue increased 3.0% year-over-year.

SEC original ↗Danaher Corporation — Earnings release (8-K exhibit)EX-99Oct 21, 2025

Free cash flowquarter

$1.4 billion

Operating cash flow was $1.7 billion and non-GAAP free cash flow was $1.4 billion.

SEC original ↗Danaher Corporation — Earnings release (8-K exhibit)EX-99Oct 21, 2025

AI analysis

Q3 2025 · reported Oct 21, 2025

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Free cash flow · Q3 2025
$1.4B
EX-99 · Oct 21, 2025
Net income · Q3 2025
$908M
EX-99 · Oct 21, 2025

Headline figures

MetricQ3 2025Prior qtrYear ago
Net income$908 million——
Revenue4.5%——
Free cash flow$1.4 billion——

EX-99 · Oct 21, 2025

Guidance · company-stated

Direction: Reiterated

Company outlook

“For full year 2025, the Company is maintaining its full year adjusted diluted net earnings per common share guidance range of $7.70 to $7.80.”

Classified from the release's primary full-year outlook statement.

Next earningsNo verified date on fileNo date is estimated or imported

Cash flow & capex

Free cash flow$1.4B

Capital allocation

With respect to the FCF Measure, we deduct payments for additions to property, plant and equipment (net of the proceeds from capital disposals) to demonstrate the amount of operating cash flow for the period that remains after accounting for the Company s capital expenditure requirements.

The Company financed the Masimo Acquisition using cash on hand and proceeds from the issuance of long-term debt and commercial paper.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Key Third Quarter 2025 Results Net earnings were $908 million, or $1.27 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.89

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Guidance & outlook

Direction: Reiterated

Company outlook: “For full year 2025, the Company is maintaining its full year adjusted diluted net earnings per common share guidance range of $7.70 to $7.80.”

Company outlook — Reiterated (“maintaining”)
“For full year 2025, the Company is maintaining its full year adjusted diluted net earnings per common share guidance range of $7.70 to $7.80.”

Classified from the release's primary full-year outlook statement.

Capital allocation

With respect to the FCF Measure, we deduct payments for additions to property, plant and equipment (net of the proceeds from capital disposals) to demonstrate the amount of operating cash flow for the period that remains after accounting for the Company s capital expenditure requirements.

SEC original ↗Danaher Corporation — Earnings release (8-K exhibit)EX-99Oct 21, 2025

The Company financed the Masimo Acquisition using cash on hand and proceeds from the issuance of long-term debt and commercial paper.

SEC original ↗Danaher Corporation — 10-Q Quarterly report10-QOct 21, 2026

Diluted net EPS from continuing operations is computed by taking net earnings from continuing operations increased by the number of additional shares that would have been outstanding had the potentially dilutive common shares been issued and reduced by the number of shares the Company could have repurchased with the proceeds from the issuance of the potentially dilutive shares.

SEC original ↗Danaher Corporation — 10-Q Quarterly report10-QOct 21, 2026

The fair value of long-term borrowings was based on quoted market prices.

SEC original ↗Danaher Corporation — 10-Q Quarterly report10-QOct 21, 2026

The difference between the fair value and the carrying amounts of long-term borrowings is attributable to changes in market interest rates and/or the Company s credit ratings subsequent to the incurrence of the borrowing.

SEC original ↗Danaher Corporation — 10-Q Quarterly report10-QOct 21, 2026

The fair values of borrowings with original maturities of one year or less, as well as cash and cash equivalents, trade accounts receivable, net and trade accounts payable generally approximate their carrying amounts due to the short-term maturities of these instruments.

SEC original ↗Danaher Corporation — 10-Q Quarterly report10-QOct 21, 2026

Strategy & priorities

Blair continued, We remain intensely focused on delivering value for our customers, associates, and shareholders.

SEC original ↗Danaher Corporation — Earnings release (8-K exhibit)EX-99Oct 21, 2025

We re investing in breakthrough innovation, enhancing our commercial execution, and driving meaningful productivity gains across our businesses.

SEC original ↗Danaher Corporation — Earnings release (8-K exhibit)EX-99Oct 21, 2025

Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow.

SEC original ↗Danaher Corporation — Earnings release (8-K exhibit)EX-99Oct 21, 2025

Restructuring Charges We exclude costs incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of the size, strategic nature and planning requirements, as well as the inconsistent frequency, of such plans) from the ongoing productivity improvements that result from application of the Danaher Business System.

SEC original ↗Danaher Corporation — Earnings release (8-K exhibit)EX-99Oct 21, 2025

ACQUISITIONS The Company continually evaluates potential acquisitions that either strategically fit with the Company s existing portfolio or expand the Company s portfolio into a new and attractive business area.

SEC original ↗Danaher Corporation — 10-Q Quarterly report10-QOct 21, 2026

Risks & headwinds

We believe these efforts will strengthen our long-term competitive position and help to solve some of the world s most difficult healthcare challenges.

SEC original ↗Danaher Corporation — Earnings release (8-K exhibit)EX-99Oct 21, 2025

Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world.

SEC original ↗Danaher Corporation — Earnings release (8-K exhibit)EX-99Oct 21, 2025

These factors include, among other things the impact of tariffs and related actions implemented by the U.

SEC original ↗Danaher Corporation — Earnings release (8-K exhibit)EX-99Oct 21, 2025

economic, political, geopolitical, legal, compliance, social and business factors (including the impact of elections, regulatory changes or uncertainty, government shutdowns and military conflicts), disruptions and other impacts relating to man-made and natural disasters, inflation and the impact of our By-law exclusive forum provisions.

SEC original ↗Danaher Corporation — Earnings release (8-K exhibit)EX-99Oct 21, 2025

Legal Proceedings 46 Item 1A.

SEC original ↗Danaher Corporation — 10-Q Quarterly report10-QOct 21, 2026

The factors used by management in its impairment analysis are inherently subject to uncertainty.

SEC original ↗Danaher Corporation — 10-Q Quarterly report10-QOct 21, 2026

Documents

Earnings deck slides

1 deck with slide view

Danaher Corporation — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Danaher Corporation — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Danaher Corporation — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care

Filings

62 documents

Earnings releases

18 documents

Presentations

4 documents

Transcripts

0 documents

No transcripts for Danaher Corporation are held in this edition of the library.

Mentioned by

7 companies

Other tracked companies whose held documents mention Danaher Corporation by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.